• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异基因造血干细胞移植治疗青少年及年轻成人急性淋巴细胞白血病

Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

机构信息

Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan; Department of Pediatrics, The University of Tokyo, Tokyo, Japan.

Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan; Graduate School of Public Health, St Luke's International University, Tokyo, Japan.

出版信息

Biol Blood Marrow Transplant. 2019 Aug;25(8):1597-1602. doi: 10.1016/j.bbmt.2019.04.014. Epub 2019 Apr 17.

DOI:10.1016/j.bbmt.2019.04.014
PMID:31002992
Abstract

Hematologic stem cell transplantation (HSCT) is the most potent consolidation therapy for high-risk acute lymphoblastic leukemia (ALL), but their outcomes and complications in adolescent and young adult (AYA) patients remain unclear. We compared outcomes after HSCT for ALL among children (age 1 to 9 years; n = 607), adolescents (age 10 to 19 years; n = 783), and young adults (age 20 to 29 years old, n = 603), based on Japanese nationwide registry data. The 5-year overall survival (OS) rate among AYA patients was worse than that of children, at 64% (95% confidence interval [CI], 60% to 68%). In the AYA, the 5-year treatment-related mortality (TRM) after HSCT was 19% (95% CI, 16% to 22%), significantly higher than that in younger patients. The most common cause of TRM in the AYA was infection. The relapse rate was not different across the 3 age groups. When focusing on older adolescents (age 15 to 19 years), there was no difference in outcomes between those treated in pediatric centers and those treated in adult centers. In conclusion, the AYA had a greater risk of nonrelapse death than younger patients, and infection was the most common cause. Further optimization is required for HSCT in AYAs with ALL.

摘要

造血干细胞移植(HSCT)是高危急性淋巴细胞白血病(ALL)最有效的巩固治疗方法,但青少年和年轻成人(AYA)患者的结果和并发症仍不清楚。我们根据日本全国登记数据比较了儿童(1 至 9 岁;n=607)、青少年(10 至 19 岁;n=783)和年轻成人(20 至 29 岁;n=603)接受 ALL 造血干细胞移植后的结果。AYA 患者的 5 年总生存率(OS)比儿童差,为 64%(95%置信区间 [CI],60%至 68%)。在 AYA 中,HSCT 后 5 年治疗相关死亡率(TRM)为 19%(95%CI,16%至 22%),显著高于年轻患者。TRM 的最常见原因是感染。3 个年龄组的复发率没有差异。当关注年龄较大的青少年(15 至 19 岁)时,在儿科中心和成人中心接受治疗的患者之间的结果没有差异。总之,AYA 患者非复发死亡的风险高于年轻患者,感染是最常见的原因。需要进一步优化 ALL 中 AYA 的 HSCT。

相似文献

1
Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.异基因造血干细胞移植治疗青少年及年轻成人急性淋巴细胞白血病
Biol Blood Marrow Transplant. 2019 Aug;25(8):1597-1602. doi: 10.1016/j.bbmt.2019.04.014. Epub 2019 Apr 17.
2
Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).造血干细胞移植治疗急性淋巴细胞白血病:为什么青少年和年轻成人的结果与儿童不同?一项代表法语国家造血干细胞移植和细胞治疗学会(SFGM-TC)的回顾性研究。
J Cancer Res Clin Oncol. 2023 Apr;149(4):1473-1483. doi: 10.1007/s00432-022-04021-1. Epub 2022 May 4.
3
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.异基因造血干细胞移植,尤其是单倍体相合移植,可能改善酪氨酸激酶抑制剂时代费城染色体阳性急性淋巴细胞白血病高危儿科患者的长期生存。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1611-1620. doi: 10.1016/j.bbmt.2018.12.007. Epub 2018 Dec 8.
4
Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后 B 前体急性淋巴细胞白血病患儿与青少年/青年患者的生存差异。
Biol Blood Marrow Transplant. 2013 Jan;19(1):138-42. doi: 10.1016/j.bbmt.2012.08.020. Epub 2012 Sep 6.
5
Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.首次完全缓解的急性白血病患者接受异基因造血干细胞移植后青少年及青年(15 - 24岁)的移植物抗宿主病
J Adolesc Young Adult Oncol. 2017 Jun;6(2):299-306. doi: 10.1089/jayao.2016.0060. Epub 2016 Dec 16.
6
[Retrospective Analysis of the Impact of Treatment on Prognosis in 44 Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia].44例青少年及青年急性淋巴细胞白血病患者治疗对预后影响的回顾性分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):14-8. doi: 10.7534/j.issn.1009-2137.2016.01.003.
7
Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP).儿童和青少年费城阳性急性淋巴细胞白血病的异基因造血干细胞移植:意大利儿科血液学和肿瘤学协会(AIEOP)的回顾性多中心研究。
Biol Blood Marrow Transplant. 2012 Jun;18(6):852-60. doi: 10.1016/j.bbmt.2011.10.015. Epub 2011 Oct 20.
8
Hematopoietic stem cell transplantation in children and adolescents with nonremission acute lymphoblastic leukemia.儿童和青少年未缓解急性淋巴细胞白血病的造血干细胞移植。
Pediatr Blood Cancer. 2020 Dec;67(12):e28732. doi: 10.1002/pbc.28732. Epub 2020 Sep 22.
9
Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.异基因造血干细胞移植治疗青少年和青年急性髓系白血病
Biol Blood Marrow Transplant. 2017 Sep;23(9):1515-1522. doi: 10.1016/j.bbmt.2017.05.009. Epub 2017 May 10.
10
Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.急性淋巴细胞白血病异基因清髓性移植后青少年及年轻成人的生存改善情况。
Biol Blood Marrow Transplant. 2014 Jun;20(6):829-36. doi: 10.1016/j.bbmt.2014.02.021. Epub 2014 Mar 7.

引用本文的文献

1
Cell therapy in pediatric blood diseases.儿科血液疾病中的细胞治疗。
Front Med (Lausanne). 2025 Jun 25;12:1591287. doi: 10.3389/fmed.2025.1591287. eCollection 2025.
2
"You Can Rest Knowing That We Know What You Want"-Longitudinal Advance Care Planning Discussions With Young Adults Receiving Hematopoietic Stem Cell Transplantation.“你可以放心,因为我们知道你想要什么”——与接受造血干细胞移植的年轻人进行的纵向预先护理计划讨论。
Psychooncology. 2025 Jun;34(6):e70189. doi: 10.1002/pon.70189.
3
Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial.
年龄和性别对1至45岁急性淋巴细胞白血病患者生存结局的影响,这些患者按照北欧儿童血液肿瘤学会(NOPHO)ALL2008试验所采用的分层方法进行治疗。
Haematologica. 2025 Aug 1;110(8):1723-1735. doi: 10.3324/haematol.2024.286043. Epub 2025 Feb 20.
4
Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.儿童急性淋巴细胞白血病的异基因造血干细胞移植
Ann Hematol. 2024 Jan;103(1):297-305. doi: 10.1007/s00277-023-05506-w. Epub 2023 Nov 22.
5
Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines.在淋巴细胞白血病细胞系中,凋亡素过表达有效增强了使用BKM120抑制PI3K的细胞毒性作用。
Adv Pharm Bull. 2022 May;12(3):613-622. doi: 10.34172/apb.2022.064. Epub 2021 Jul 10.
6
Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).造血干细胞移植治疗急性淋巴细胞白血病:为什么青少年和年轻成人的结果与儿童不同?一项代表法语国家造血干细胞移植和细胞治疗学会(SFGM-TC)的回顾性研究。
J Cancer Res Clin Oncol. 2023 Apr;149(4):1473-1483. doi: 10.1007/s00432-022-04021-1. Epub 2022 May 4.
7
Linear and Circular Long Non-Coding RNAs in Acute Lymphoblastic Leukemia: From Pathogenesis to Classification and Treatment.线性和环状长非编码 RNA 在急性淋巴细胞白血病中的作用:从发病机制到分类和治疗。
Int J Mol Sci. 2022 Apr 18;23(8):4442. doi: 10.3390/ijms23084442.
8
Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges.青少年和青年急性淋巴细胞白血病患者的造血干细胞移植:特殊考量与挑战
Front Pediatr. 2022 Jan 11;9:796426. doi: 10.3389/fped.2021.796426. eCollection 2021.
9
MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.基于微小残留病的青少年和青年费城阴性急性淋巴细胞白血病基因定义亚组的治疗决策
Cancers (Basel). 2021 Apr 27;13(9):2108. doi: 10.3390/cancers13092108.
10
The value of F-FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation.F-FDG PET/CT在预测接受异基因造血干细胞移植的急性白血病患者临床结局中的价值
Oncol Lett. 2020 Nov;20(5):175. doi: 10.3892/ol.2020.12036. Epub 2020 Aug 31.